Growth Hormone News and Research RSS Feed - Growth Hormone News and Research

Growth hormone (GH) is a protein-based peptide hormone. It stimulates growth, cell reproduction and regeneration in humans and other animals. Growth hormone is a 191-amino acid, single-chain polypeptide that is synthesized, stored, and secreted by the somatotroph cells within the lateral wings of the anterior pituitary gland.
Drug for reduction of abdominal fat in HIV patients may also reduce fatty liver disease

Drug for reduction of abdominal fat in HIV patients may also reduce fatty liver disease

The only drug to receive FDA approval for reduction of the abdominal fat deposits that develop in some patients receiving antiviral therapy for HIV infection may also reduce the incidence of fatty liver disease in such patients. [More]
Growth hormone reduces liver fat in HIV-infected patients with excess abdominal fat

Growth hormone reduces liver fat in HIV-infected patients with excess abdominal fat

In a preliminary study, HIV-infected patients with excess abdominal fat who received the growth hormone-releasing hormone analog tesamorelin for 6 months experienced modest reductions in liver fat, according to a study in the July 23/30 issue of JAMA, a theme issue on HIV/AIDS. [More]
Marmoset's unique rapid reproductive system sheds new light on evolution and primate biology

Marmoset's unique rapid reproductive system sheds new light on evolution and primate biology

A team of scientists from around the world led by Baylor College of Medicine and Washington University in St. Louis has completed the genome sequence of the common marmoset - the first sequence of a New World Monkey - providing new information about the marmoset's unique rapid reproductive system, physiology and growth, shedding new light on primate biology and evolution. [More]
Dosing commences in Essentialis’ DCCR clinical study in obese Prader-Willi syndrome patients

Dosing commences in Essentialis’ DCCR clinical study in obese Prader-Willi syndrome patients

Essentialis announced today the dosing of the first patient in clinical study PC025, which is designed to evaluate the safety and efficacy of diazoxide choline controlled release tablets (DCCR) in obese Prader-Willi syndrome patients. [More]
New study finds that GH treatment could lead to depression in children

New study finds that GH treatment could lead to depression in children

Short, otherwise healthy children who are treated with growth hormone (GH) may become taller, but they may also become more depressed and withdrawn over time, compared to children the same age and height who are not treated with GH, a new study finds. [More]
Growth hormone deficiency may protect people from developing Type 2 diabetes, cancer

Growth hormone deficiency may protect people from developing Type 2 diabetes, cancer

People who lack growth hormone (GH) receptors also appear to have marked insulin sensitivity that prevents them from developing diabetes and lowers their risk for cancer, despite their increased percentage of body fat, new research finds. [More]
Childhood oestrogen may normalise thelarche in Turner syndrome

Childhood oestrogen may normalise thelarche in Turner syndrome

Treating girls with Turner syndrome with low-dose oestrogen from childhood results in earlier thelarche and a slower tempo of puberty, research shows. [More]
‘Surprising’ effect of growth hormone on BMI in normal-weight children

‘Surprising’ effect of growth hormone on BMI in normal-weight children

Researchers have found that the body mass index standard deviation score increases in normal-weight children receiving growth hormone treatment. [More]
Growth hormone levels may manifest in signs of aging

Growth hormone levels may manifest in signs of aging

The decreased production of growth hormone is caused by a physiological process known as somatopause, which practically affects the entire body, since it's involved in body composition, metabolism, bone mineral density and cardiovascular function. [More]
USPTO grants two additional patents to SeroVital-hgh formula

USPTO grants two additional patents to SeroVital-hgh formula

SeroVital®-hgh, the "Fountain of Youth" Formula everyone's talking about, has been making headlines ever since a group of some of the most renowned researchers in the world revealed that this oral compound is actually capable of increasing mean, endogenous, serum (blood) human growth hormone (hGH) levels by 682%. Experts everywhere — from dermatologists and obesity researchers to women's healthcare providers and even the famed Dr. Oz himself — began paying attention to this groundbreaking formula. [More]
Antares Pharma reports total revenues of $5.2 million for first quarter 2014

Antares Pharma reports total revenues of $5.2 million for first quarter 2014

Antares Pharma, Inc. today reported operating and financial results for the first quarter ended March 31, 2014. [More]
Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Novartis today presented results from a pivotal Phase III trial of investigational therapy Signifor® LAR (pasireotide LAR; SOM230) in patients with acromegaly for whom current standard of care provides inadequate disease control. [More]
Two endocrinology societies announce comprehensive framework to combat obesity

Two endocrinology societies announce comprehensive framework to combat obesity

Calling it the most under-reimbursed major disease in America, two endocrinology societies announced an evidence-based, multidimensional, comprehensive framework to combat the nation's obesity epidemic today. [More]
Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

Janssen Research & Development, LLC ("Janssen") today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA™ (ibrutinib) to the U.S. Food and Drug Administration (FDA) by its collaboration partner Pharmacyclics, Inc. [More]
Antisense Therapeutics enrolls acromegalic patients in ATL1103 Phase II trial

Antisense Therapeutics enrolls acromegalic patients in ATL1103 Phase II trial

Antisense Therapeutics Limited is pleased to report that 24 acromegalic patients have been successfully enrolled and randomized to one of the two treatment regimens of dosing in the Phase II trial of ATL1103 for the growth disorder, acromegaly. This satisfies the necessary patient numbers proposed for the trial. [More]
Antares Pharma reports total revenue of $4.7 million for fourth quarter 2013

Antares Pharma reports total revenue of $4.7 million for fourth quarter 2013

Antares Pharma, Inc. today reported operating and financial results for the fourth quarter and full year ended December 31, 2013. [More]
Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma, Inc. today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. [More]
Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Safeguard Scientifics, Inc. today announced fourth quarter and full-year 2013 financial results. For the three months ended December 31, 2013, Safeguard's net income was $24.0 million, or $1.10 per share, compared to net loss of $10.8 million, or $0.51 per share for the same period in 2012. For the year ended December 31, 2013, Safeguard's net loss was $35.5 million, or $1.66 per share, compared to $39.4 million, or $1.88 per share for the same period in 2012. [More]
Eating high-protein diet in middle age is as deadly as smoking

Eating high-protein diet in middle age is as deadly as smoking

That chicken wing you're eating could be as deadly as a cigarette. In a new study that tracked a large sample of adults for nearly two decades, researchers have found that eating a diet rich in animal proteins during middle age makes you four times more likely to die of cancer than someone with a low-protein diet - a mortality risk factor comparable to smoking. [More]
OPKO Health consolidated revenues increase about 30% to $20.7 million in Q4 2013

OPKO Health consolidated revenues increase about 30% to $20.7 million in Q4 2013

OPKO Health, Inc., a multi-national biopharmaceutical and diagnostics company, today reported operating and financial results for its 2013 fourth quarter and full year ended December 31, 2013. [More]